News
Zacks.com on MSN12h
ABBV or BMY: Which Biopharma Giant Has Better Prospects for Now?AbbVie edges ahead of Bristol Myers with strong Skyrizi and Rinvoq growth, offsetting Humira declines and portfolio headwinds.
Zacks.com on MSN3d
How Will Skyrizi and Rinvoq Sales Aid AbbVie's Upcoming Q2 Results?AbbVie ABBV has successfully navigated the loss of exclusivity (LOE) for its flagship drug, Humira, by launching two newer ...
The author includes U.S. and Canadian names, organized by country. Each company comes with a business summary, plus a bull ...
The global Botulinum Toxins Market, valued at US$8.1 billion in 2024 stood at US$8.9 billion in 2025 and is projected to advance at a ...
The pharma began its outreach to the HS community well before securing Bimzelx’s approval in the indication. In the spring of ...
AbbVie has broken ground on a new $223 million expansion of its biologics manufacturing facility in Singapore, creating around 100 new jobs.
AbbVie makes its tariffs-driven investment play AbbVie has become the latest pharma group to make a big capital investment announcement in the US and court favour with the Trump administration.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback